ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0064 • ACR Convergence 2025

    Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice

    Tailin He and Yifang Mei, Shenzhen Third People's Hospital, Shenzhen, China (People's Republic)

    Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…
  • Abstract Number: 0006 • ACR Convergence 2025

    QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis

    Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
  • Abstract Number: 2639 • ACR Convergence 2025

    Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis

    VINOD GUPTA1, Adam Koller1, Benjamin Hur1, Marissa Bailey1, Kara Delger2, Elena myasoedova1, Vanessa Kronzer1, John Davis1 and Jaeyun Sung1, 1Mayo Clinic, ROCHESTER, MN, 2Mayo Clinic, St Charles, MN

    Background/Purpose: Oral methotrexate (MTX) is the cornerstone treatment for newly diagnosed rheumatoid arthritis (RA), yet up to 50% of patients do not respond adequately. Early…
  • Abstract Number: 2288 • ACR Convergence 2025

    Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial

    Yuan Xue, Bo Wei, Xiaojing Huang and Rui Ding, Zhongshan Hospital Xiamen University, Xiamen, China (People's Republic)

    Background/Purpose: Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA). This post-hoc study aimed to evaluate…
  • Abstract Number: 2272 • ACR Convergence 2025

    Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort

    Francesco NATALUCCI1, Cécile VAN MULLEM1, Aleksandra AVRAMOVSKA1, Tatiana SOKOLOVA2 and Patrick Durez1, 1Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation. Several bDMARDs and tsDMARDs target different key players in the immune-regulatory pathways,…
  • Abstract Number: 2256 • ACR Convergence 2025

    Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study

    Qurat Ul Ain1 and MIrza faris Ali Baig2, 1Medstar Georgetown University Hospital, Arlington, VA, 2Medstar Health, Arlington, VA

    Background/Purpose: The increased risk of cardiovascular morbidity and mortality with rheumatoid arthritis has been increasingly acknowledged over the past decades. Cardiovascular disease risk management for…
  • Abstract Number: 2240 • ACR Convergence 2025

    Diabetes Significantly Amplifies Risk of Cardiac Arrhythmias in Rheumatoid Arthritis Patients: Results from a Multi-Center Electronic Health Record Study

    Godbless Ajenaghughrure1, Sila Mateo Faxas2, Gurjot Singh3, Nirys Mateo Faxas4, Kim Nguyen3, Nicole Tejeda5 and Kimberly Ramirez Bonetti6, 1Trihealth Good Samaritan Hospital, Cincinnati, OH, 2Good Samaritan Hospital, Cincinnati, OH, 3Trihealth Good Samaritan Hospital, Cincinnati, 4Independent Author, Santo Domingo, Dominican Republic, 5Independent Author, Cincinnati, 6Independent Author, cincinnati, OH

    Background/Purpose: Both rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) are independently associated with increased cardiovascular risk. However, the impact of T2DM on cardiac…
  • Abstract Number: 2197 • ACR Convergence 2025

    Mechanisms of Fetal Growth Restriction in Rheumatologic Autoimmune Diseases: Insights into Placental Pathology and Immune Dysregulation

    Larabe Farrukh1, Ananya Venkatesh2, Mana Parast2 and Chelsey Smith3, 1University of California San Diego, San Diego, CA, 2University of California San Diego, San Diego, 3University of California San Diego, LA JOLLA, CA

    Background/Purpose: Fetal growth restriction (FGR) significantly contributes to adverse pregnancy outcomes (APOs) in women with rheumatologic diseases. Understanding the immunopathologic mechanisms underlying FGR is critical…
  • Abstract Number: 1947 • ACR Convergence 2025

    Coronary computed tomography incidental findings in rheumatoid arthritis.

    Emmanuel Tapia López1, Jessica Roldan Ortega2, Evelyn Aranda Cano3, Itzel Palafox Sosa4, Luz Viruel5, Luis H Silveira6, Laura Aline Martinez-Martinez7 and Francisco Castillo-Castellon8, 1Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Naucalpan de Juarez, Estado de México, Mexico, 2INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Federal District, Mexico, 3Departament of rheumatology Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Federal District, Mexico, 4Escuela Superior de Medicina-Instituto Politècnico Nacional, ciudad de mexico, Federal District, Mexico, 5Universidad Autónoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, 6Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 7Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, 8Instituto Nacional de Cardiología Ignacio Chavez, Mexico

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a greater cardiovascular risk than does the general population. The coronary calcium score is a measure used to…
  • Abstract Number: 1880 • ACR Convergence 2025

    Rheumatoid Arthritis Mortality in the U.S. (1999–2020): A Decline in Rates, But Not in Disparities

    Aziz-ur-Rahman Khalid1, Ghassan Makhoul2, Hasan Munshi2, Islam Rajab2, Emmanuel Olumuyide3, MD Walid Akram Hussain2, Aqsa Sorathia2, Elvira Assaf2, Amer Al Badawy2, John Salama2 and Robert Lahita4, 1St. Joseph's University Medical Center, wayne, 2St. Josephs University Medical Center, Paterson, 3Advocate Illinois Masonic Medical Center, Chicago, 4St. Josephs University Medical Center, Wayne, NJ

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with increased morbidity and mortality. While treatments have evolved, national trends and sociodemographic disparities in…
  • Abstract Number: 1692 • ACR Convergence 2025

    Rheumatoid factor is associated with increased gut permeability and migration of B cells to the joint via CXCR3 in rheumatoid arthritis

    Ken Yasaka1, Nida Pellett2, Daria Krenitsky1 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical center, Rochester, NY

    Background/Purpose: It has been proposed that the mucosal environment is associated with the pathogenesis of rheumatoid arthritis (RA). In addition to gut dysbiosis, intestinal barrier…
  • Abstract Number: 1387 • ACR Convergence 2025

    Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network

    Jeffrey Curtis1, Emily Holladay2, Antton Egana3, Anjana Lalla3, Yujie Su4, Fenglong Xie5, Amy Mudano4, Shanette Daigle4 and Sara McCoy6, 1Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 2University of Alabama at Birmingham, Edmond, OK, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, 5The University of Alabama at Birmingham, Birmingham, AL, 6University of Wisconsin–Madison, Madison, WI

    Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disease characterized by systemic symptoms such as dryness, fatigue, musculoskeletal pain, and extraglandular manifestations. SjD may overlap…
  • Abstract Number: 1359 • ACR Convergence 2025

    Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

    Maya Khasho1, Ahmad Alomari2, Reem Elmusa3 and Rafal Ali4, 1University of central florida, Gainesville, FL, 2UCF- North Florida hospital, Gainesville, FL, 3UCF/ HCA - North florida hospital, Gainesville, FL, 4Jefferson Einstein Philadelphia, Lansdale, PA

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease affecting synovial joints, often leading to joint destruction if untreated. Disease-modifying antirheumatic drugs (DMARDs), including Janus…
  • Abstract Number: 1342 • ACR Convergence 2025

    The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis

    Saskia Truijen1, Annelies Boonen1, Sofia Ramiro2 and Marloes van Onna1, 1Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, 2Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: As the population ages, rheumatologists will increasingly care for older persons with rheumatoid arthritis (RA). Aging comes with specific challenges of which rheumatologists are…
  • Abstract Number: 1325 • ACR Convergence 2025

    Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis

    Tate Johnson1, Michael Duryee1, Punyasha Roul2, Grant Cannon3, Gary Kunkel4, Beth Wallace5, Isaac Smith6, John Richards7, Katherine Wysham8, Gail Kerr9, Andreas Reimold10, Pascale Schwab11, Daniel Anderson12, Joshua Baker13, Geoffrey Thiele1, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3University of Utah and Salt Lake City VA, Salt Lake City, UT, 4University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 5Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 6Duke University Hospital, Durham, NC, 7Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 8VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 9Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 10Dallas VA Medical Center, Dallas, TX, 11VA Portland and Oregon Health & Science University, Portland, OR, 120587964, Durham, NC, 13University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The mechanisms of heart failure (HF) risk in RA remain incompletely understood. HF with preserved ejection fraction (HFpEF) is over-represented in RA, which may…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology